Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3321-3326

  Vicente, Esther ^a   Villar, Raquel ^a   Burguete, Asunción ^a   Solano, Beatriz ^a   Pérez Silanes, Silvia ^a   Aldana, Ignacio ^a   Maddry, Joseph A ^c   Lenaerts, Anne J ^d   Franzblau, Scott G ^e   Cho, Sang Hyun ^e   Monge, Antonio ^a   Goldman, Robert C ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d Department of Environmental and Radiological Health Sciences   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ETHYL 7 CHLORO 3 METHYLQUINOXALINE 2 CARBOXYLATE 1,4 DIOXIDE; NICLOSAMIDE; NITROIMIDAZOLE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; IN VITRO STUDY; IN VIVO STUDY; LUNG; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CYCLIC N-OXIDES; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LUNG; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUINOXALINES; SPECIFIC PATHOGEN-FREE ORGANISMS; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 50949110277     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00379-08     Document Type: Article

References (32)

1. Abreu, F. C., M. O. Goulart, and A. M. Brett. 2002. Detection of the damage caused to DNA by niclosamide using an electrochemical DNA-biosensor. Biosens. Bioelectron. 17:913-919.
2. Benatar, S. R. 2006. Extensively drug resistant tuberculosis: problem will get worse in South Africa unless poverty is alleviated. Br. Med. J. 333:705.
3. Cho, S. H., S. Warit, B. J. Wan, C. H. Hwang, G. F. Pauli, and S. G. Franzblau. 2007. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51:1380-1385.
4. 420 biosynthesis by Mycobacterium bovis BCG. J. Bacteriol. 183:7058-7066.
5. 420 and FO biosynthesis. J. Bacteriol. 184:2420-2428.
6. Cooper, A. M., D. K. Dalton, T. A. Stewart, J. P. Griffin, D. G. Russell, and I. M. Orme. 1993. Disseminated tuberculosis in interferon-gamma gene-disrupted mice. J. Exp. Med. 178:2243-2247.
7. Dahle, U. R. 2006. Extensively drug resistant tuberculosis: beware patients lost to follow-up. Br. Med. J. 333:705.
8. Dye, C., and M. A. Espinal. 2001. Will tuberculosis become resistant to all antibiotics? Proc. Biol. Sci. 268:45-52.
9. Espinal, M. A. 2003. The global situation of MDR-TB. Tuberculosis 83:44-51.
10. Franzblau, S. G., R. S. Witzig, J. C. McLaughlin, P. Torres, G. Madico, A. Hernandez, M. T. Degnan, M. B. Cook, V. K. Quenzer, R. M. Ferguson, and R. H. Gilman. 1998. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol. 36:362-366.
11. Gandhi, N. R., A. Moll, A. W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews, and G. Friedland. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580.
12. Goldman, R. C., K. V. Plumley, and B. E. Laughon. 2007. The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control. Infect. Disord. Drug Targets 7:73-91.
13. Gruppo, V., C. M. Johnson, K. S. Marietta, H. Scherman, E. E. Zink, D. C. Crick, L. B. Adams, I. M. Orme, and A. J. Lenaerts. 2006. Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 50: 1245-1250.
14. Jaso, A., B. Zarranz, I. Aldana, and A. Monge. 2003. Synthesis of new 2-acetyl and 2-benzoyl quinoxaline 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. Eur. J. Med. Chem. 38:791-800.
15. Jaso, A., B. Zarranz, I. Aldana, and A. Monge. 2005. Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-Mycobacterium tuberculosis agents. J. Med. Chem. 48:2019-2025.
16. Lawn, S. D., and R. Wilkinson. 2006. Extensively drug resistant tuberculosis: a serious wake-up call for global health. Br. Med. J. 333:559-560.
17. Lenaerts, A. J., V. Gruppo, K. S. Marietta, C. M. Johnson, D. K. Driscoll, N. M. Tompkins, J. D. Rose, R. C. Reynolds, and I. M. Orme. 2005. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49:2294-2301.
18. Lenaerts, A. J. M., V. Gruppo, J. V. Brooks, and I. M. Orme. 2003. Rapid in vivo screening of experimental drugs for tuberculosis using gamma interferon gene-disrupted mice. Antimicrob. Agents Chemother. 47:783-785.
19. Manissero, D., and K. Fernandez de la Hoz. 2006. Extensive drug-resistant TB: a threat for Europe? Euro Surveill. 11:E060928.
20. Manjunatha, U. H., H. Boshoff, C. S. Dowd, L. Zhang, T. J. Albert, J. E. Norton, L. Daniels, T. Dickl, S. S. Pang, and C. E. Barry. 2006. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 103:431-436.
21. Migliori, G. B., G. De Iaco, G. Besozzi, R. Centis, and D. M. Cirillo. 2007. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill. 12:E070517.1.
22. Montoya, M. E., Y. Sainz, M. A. Ortega, A. L. De Cerain, and A. Monge. 1998. Synthesis and antituberculosis activity of some new 2-quinoxalinecarbonitriles. Farmaco 53:570-573.
23. Orme, I., J. Secrist, S. Anathan, C. Kwong, J. Maddry, R. Reynolds, A. Poffenberger, M. Michael, L. Miller, J. Krahenbuh, L. Adams, A. Biswas, S. Franzblau, D. Rouse, D. Winfield, and J. Brooks. 2001. Search for new drugs for treatment of tuberculosis. Antimicrob. Agents Chemother. 45: 1943-1946.
24. Ortega, M. A., M. E. Montoya, A. Jaso, B. Zarranz, I. Tirapu, I. Aldana, and A. Monge. 2001. Antimycobacterial activity of new quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives. Pharmazie 56:205-207.
25. Ortega, M. A., Y. Sainz, M. E. Montoya, A. L. De Cerain, and A. Monge. 1999. Synthesis and antituberculosis activity of new 2-quinoxalinecarbonitrile 1,4-di-N-oxides. Pharmazie 54:24-25.
26. Ortega, M. A., Y. Sainz, M. E. Montoya, A. Jaso, B. Zarranz, I. Aldana, and A. Monge. 2002. Anti-Mycobacterium tuberculosis agents derived from quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide. Arzneimittel-Forsch. 52:113-119.
27. Sainz, Y., M. E. Montoya, F. J. Martinez-Crespo, M. A. Ortega, A. L. de Cerain, and A. Monge. 1999. New quinoxaline 1,4-di-N-oxides for treatment of tuberculosis. Arzneimittel-Forsch. 49:55-59.
28. Shah, N. S., R. Pratt, S. Althomsons, and J. P. Cegielski. 2007. Extensively drug-resistant tuberculosis, United States, 1993-2006. JAMA 297: 1871-1873. [Reprinted from MMWR Morb. Mortal. Wkly. Rep. 56:250-253, 2007.]
29. Suter, W., A. Rosselet, and F. Knusel. 1978. Mode of action of quindoxin and substituted quinoxaline-di-N-oxides on Escherichia coli. Antimicrob. Agents Chemother. 13:770-783.
30. White, E. L., W. J. Suling, L. J. Ross, L. E. Seitz, and R. C. Reynolds. 2002. 2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ. J. Antimicrob. Chemother. 50:111-114.
31. World Health Organization. March 2006, posting date. Strategic and technical meeting on intensified control of neglected tropical diseases. A renewed effort to combat entrenched communicable diseases of the poor. World Health Organization, Geneva, Switzerland. http://www.popline.org/ docs/312474.
32. Zarranz, B., A. Jaso, I. AIdana, and A. Monge. 2003. Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives. Bioorg. Med. Chem. 11:2149-2156.